

November 7, 2021

**To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001**

Ref: Scrip Code: 543322

**To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051**

Ref: Scrip Name: GLS

Dear Sirs,

Sub:- Consideration of Interim Dividend

In continuation to our Board meeting intimation dated November 1, 2021 and pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting scheduled to be held on Wednesday, November 10, 2021 will also consider proposal for payment of interim Dividend to members of the Company for the Financial year 2021-22.

The above is for your information.

Thanking you

Yours faithfully,
For Glenmark Life Sciences Limited

**Rudalf Corriea
Company Secretary & Compliance Officer**

Glenmark Life Sciences Limited

Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai 400 099, India.

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpath, Solapur - 413 213, India.

T: 91 22 68297979 CIN: U74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com W: www.glenmarklifesciences.com